The price of Enhabit Inc. (NYSE:EHAB) shares last traded on Wall Street fell -4.94% to $14.06.
Based on available information, 8 analysts follow Enhabit Inc. (NYSE:EHAB). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $20.00 and a low of $12.00, we find $18.00. Given the previous closing price of $14.79, this indicates a potential upside of 21.7 percent. EHAB stock price is now -2.34% away from the 50-day moving average and -6.40% away from the 200-day moving average. The market capitalization of the company currently stands at $698.50M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Among analysts, 4 rate the stock a hold while 2 rate it a buy. Brokers who have rated the stock have averaged $16.14 as their price target over the next twelve months.
With the price target of $18, CJS Securities recently initiated with Market Perform rating for Enhabit Inc. (NYSE: EHAB). On December 08, 2022, UBS recently initiated its ‘Sell’ rating on the stock quoting a target price of $12, while ‘Stifel’ rates the stock as ‘Buy’.
In other news, Bolton Jeffrey, Director bought 1,000 shares of the company’s stock on Nov 18. The stock was bought for $12,690 at an average price of $12.69. Upon completion of the transaction, the Director now directly owns 15,597 shares in the company, valued at $0.22 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 09, Director Bolton Jeffrey bought 2,000 shares of the business’s stock. A total of $25,500 was incurred on buying the stock at an average price of $12.75. This leaves the insider owning 14,597 shares of the company worth $0.21 million. Insiders disposed of 3,853,248 shares of company stock worth roughly $54.18 million over the past 1 year. A total of 1.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EHAB stock. A new stake in Enhabit Inc. shares was purchased by CRUISER CAPITAL ADVISORS, LLC during the first quarter worth $12,729,000. BANK OF NOVA SCOTIA invested $1,518,000 in shares of EHAB during the first quarter. In the first quarter, CINCTIVE CAPITAL MANAGEMENT LP acquired a new stake in Enhabit Inc. valued at approximately $1,445,000. FIRST REPUBLIC INVESTMENT MANAGEMENT, INC. acquired a new stake in EHAB for approximately $885,000. JANE STREET GROUP, LLC purchased a new stake in EHAB valued at around $729,000 in the second quarter. In total, there are 306 active investors with 97.40% ownership of the company’s stock.
A candlestick chart of Enhabit Inc. (NYSE: EHAB) showed a price of $14.77 on Monday morning. During the past 12 months, Enhabit Inc. has had a low of $11.65 and a high of $25.25. As of last week, the company has a debt-to-equity ratio of 0.68, a current ratio of 1.50, and a quick ratio of 1.50. The fifty day moving average price for EHAB is $14.40 and a two-hundred day moving average price translates $15.08 for the stock.
The latest earnings results from Enhabit Inc. (NYSE: EHAB) was released for Sep, 2022. The company reported revenue of $275.1 million for the quarter, compared to $276.1 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -0.36 percent. For the current quarter, analysts expect EHAB to generate $267.86M in revenue.
Enhabit Inc.(EHAB) Company Profile
Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer’s disease, low vision, spinal stenosis, Parkinson’s disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company also offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. As of March 31, 2022, it operated in 252 home health agencies and 99 hospice agencies across 34 states. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was incorporated in 2014 and is headquartered in Dallas, Texas. As of July 1, 2022, Enhabit, Inc. operates as a standalone company.
